GleamWall
中文EN

AMRX Amneal Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1723128 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.9%
TTM net income YoY2,159.3%
TTM EPS YoY3,900.0%
Revenue 3-yr CAGR10.2%
Net income 3-yr CAGR270.1%

Margins

Gross margin40.2%
Operating margin15.0%
Net margin4.2%
FCF margin2.8%
EBITDA margin—

Returns

ROE63.2%
ROA3.0%
ROIC (approx.)16.3%
Asset turnover0.72x

Leverage & solvency

Liabilities / assets87.8%
Debt / equity5.53x
Current ratio1.87x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.36x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$3.02B$2.79B
Cost of revenue$1.91B$1.77B
Gross profit$1.11B$1.02B
R&D expense$186.18M$190.71M
SG&A expense$526.83M$476.44M
Operating income$394.10M$249.33M
Pretax income$139.21M-$55.01M
Income tax$11.28M$18.86M
Net income$72.06M-$116.89M
EBITDA$451.40M$311.93M
EPS (basic)0.23-0.38
EPS (diluted)0.22-0.38
Weighted avg. shares (diluted)324.81M308.98M
Balance sheet
Cash & equivalents$282.03M$118.42M
Inventory$606.30M$612.45M
Current assets$1.91B$1.59B
PP&E, net$442.95M$424.91M
Goodwill$595.47M$597.44M
Intangibles$563.50M$732.38M
Total assets$3.68B$3.50B
Current liabilities$881.63M$1.13B
Short-term debt$6.76M$224.21M
Long-term debt$2.57B$2.16B
Total debt$2.57B$2.39B
Total liabilities$3.67B$3.55B
Shareholders' equity-$70.79M-$109.27M
Net debt$2.29B$2.27B
Cash flow statement
Operating cash flow$339.99M$295.10M
Capital expenditure$70.06M$51.92M
Free cash flow$269.93M$243.18M
Investing cash flow-$112.26M-$63.00M
Financing cash flow-$31.53M-$211.79M
Depreciation & amortization$57.30M$62.60M
Stock-based compensation$31.95M$27.77M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.